Tumores germinales

  1. Bernier García, L. 1
  2. Sánchez Cendra, C. 1
  3. Mohedano Mohedano, N. 1
  4. Peñas Pita da Veiga, M. 1
  5. Nalda Arija, I. 1
  6. Cassinello Espinosa, J. 1
  1. 1 Unidad de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Enfermedades oncológicas (III) Tumores genitourinarios

Series: 13

Issue: 26

Pages: 1467-1472

Type: Article

DOI: 10.1016/J.MED.2021.02.014 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Testicular germ cell tumors (TGCT) are rare and represent only 1% of all malignant tumors in males, but are the most frequent neoplasm in individuals between 15 and 35 years of age. Its worldwide incidence has increased in recent years and the mortality rate has gradually decreased thanks to advances in modern chemotherapy, improvements in supportive care, earlier diagnosis, and cumulative experience in its comprehensive treatment. It has a general 5-year survival rate of 95%. Treatment is based on surgery and well-established chemotherapy schedules. At the moment, no new generation drugs are available, perhaps due to reticence to try a new treatment when there is one that is already consolidated and with a high degree of definitive recovery. In fact, these tumors can be considered a model par excellence for cancer cures.

Bibliographic References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
  • Batata MA, Chu FC, Hilaris BS, Whitmore WF, Golbey RB. Testicular cancer in cryptorchids. Cancer. 1982;49(5):1023-30.
  • Holm M, Hoei-Hansen CE, Rajpert-De Meyts E, Skakkebaek NE. Increased risk of carcinoma in situ in patients with testicular germ cell cancer with ultrasonic microlithiasis in the contralateral testicle. J Urol. 2003;170(4 Pt 1):1163-7.
  • Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67.
  • Bosl GJ, Motzer RJ. Testicular germcell cancer. N Engl J Med. 1997; 337(4):242-53.
  • Tseng A Jr, Horning SJ, Freiha FS, Resser KJ, Hannigan JF Jr, Torti FM. Gynecomastia in testicular cancer patients: Prognostic and therapeutic implications. Cancer. 1985;56(10):2534-8.
  • Benson CB. The role of ultrasound in diagnosis and staging of testicular cancer. Semin Urol. 1988;6(3):189-202.
  • Schultz-Lampel D, Bogaert G, Thüroff JW, Schlegel E, Cramer B. MRI for evaluation of scrotal pathology. Urol Res. 1991;19(5):289-92.
  • de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, et al. [18F]-FDG-PET in clinical stageI and II nonseminomatous germ cell tumors: first results of the german multicenter trial (abstract). J Clin Oncol. 2005;23:379s.
  • Huddart RA, O’Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, et al. NCRI Testis Tumour Clinical Study Group 18fluoro-deoxyglucose positron emission tomography in the prediction of relapse in patients with highrisk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol. 2007; 25(21):3090-5.
  • Brimo F, Srigley JR, Ryan CJ, et al. Testis. En: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017. p. 727.
  • International Germ Cell Consensus Classification: a prognostic factorbased staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594-603.
  • Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C, et al. Longterm effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer. 1999;80(5-6):801-7.
  • Stenning S, Oliver T, Mead B, Gabe R. Carboplatin in clinical stage I seminoma: a valuable option for patient management. J Clin Oncol. 2011;29(31):4210-1.
  • Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol. 2007;64(3):182-97.
  • Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management pro-gram. J Clin Oncol. 2009;27(13):2122-8.
  • Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Hei-denreich A, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966-72.
  • Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, et al; ESMO Guidelines Working Group. Testicular seminoma. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann On-col. 2010;21Suppl5:v140-6.
  • Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O’Malley M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J. 2010;4(2):e19-38.
  • Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germcell testicular cancer. J Clin Oncol. 2007;25(35):5597-602.
  • Chung PW, Bedard P. Stage II seminomas and nonseminomas. Hematol Oncol Clin North Am. 2011;25(3):529-41.
  • Ravi P, Gray KP, O’Donnell EK, Sweeney CJ. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor. Ann Oncol. 2014; 25(2):331-8.
  • International Germ Cell Consensus Classification: a prognostic factorbased staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594-603.
  • Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cispla-tin is an effective second-line therapy for patients with relapsed tes-ticular germ cell tumors. J Clin Oncol. 2005;23(27):6549-55.
  • Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988;109(7): 540-6.
  • Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29(16):2178-84.
  • Lorch A, Kleinhans A, Kramar A, Kollmannsberger CK, Hart-mann JT, Bokemeyer C, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tu-mors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30(8):800-5.
  • Oldenburg J, Martin JM, Fossa DS. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol. 2006;24(35): 5503-11.
Data source: Dialnet